Marbls

Our company, Marbls, is five (5) years old and we just couldn’t be happier! The best thing about our company is the great people we work with daily on our team. They are super nice, from various parts of the world, and really great at what they do in Life Sciences.    A big thanks to our clients and partners. We look forward to many years to come!   Please take a look as #ourteam, says “Hi!” Ralph Lynn Arnab Sikder

A great few days (and evenings) for our Marbls team in Amsterdam this week at the World Evidence and Pricing Access (EPA) Congress! Quinn McCartney, Raquel Cunha Santos, and Ruven Remo Eul had an opportunity to spend quality time with our clients and partners diving deep into various topics. With the start of the year well underway, our clients continue to look at ways to address their key business and tech needs within Pricing and Access – and we’re here to support them.   A great way to cap off the event this afternoon with Raquel Santos and Ruven Eul’s presentation on the topic of "Successful Value Retention through Effective Loss of Exclusivity (LoE)."   If you have questions on what was discussed at the World EPA, our presentation, or any additional topics, please contact Quinn, Raquel, or Ruven or anyone on our Marbls team!   Ralph Lynn Arnab Sikder

Activities related to the Drug Pricing Negotiation Program associated with the IRA’s Maximum Fair Price (MFP) component are heating up!  Last week was the deadline for manufacturers selected for Price Applicability Year 2027 to confirm participation and to share drug and manufacturer specific data to be considered as part of the negotiation process. Coming soon in April, CMS will host Roundtable events (one for each drug selected) to facilitate discussions among patients, patient advocacy organizations, and caregivers about their experiences and perspectives on each selected drug.  Similarly, CMS will host two town hall events at the end of April to focus on the clinical considerations related to the selected drugs, providing a platform for clinicians, researchers, and other interested parties to share their insights. Following the Spring activity, manufacturers will be standing by awaiting CMS’ initial price offer for their selected drug(s), due by June 1st.  We’ll continue to provide key updates as the negotiations progress! And coming soon, we’ll be releasing our first installment of our IRA White Paper series, focused exclusively on MFP. In the meantime, feel free to reach out to anyone on the Marbls team or themarblsteam@marblsgroup.com for further insights on any of the IRA components. #lifesciences #pricing #contracting #medicareupdates #geneva #princetonnj #wth #lisbon Amber Daly Arnab Sikder Ralph Lynn

Marbls is pleased to announce our sponsorship of the Model N Rainmaker Conference in Austin, TX from May 28th – May 30th, 2025! We always look forward to this amazing event especially with this year being the 25th anniversary!  Our team is excited to be in Austin that week to join our clients and partners in discussing many key industry topics and trends such as impacts from the Inflation Reduction Act, the latest 340B changes, State Price Transparency Reporting, drug launch planning, and preparing for Loss of Exclusivity (LOE) in the US and international markets! Additional information will be shared in the upcoming weeks leading up to the event. For now, feel free to email us at  themarblsteam@marblsgroup.com for additional details on the event. We hope to see you in Austin!  #lifesciences #pricing #contracting #marketaccess #revenuemanagement #ira #loe #tendering #geneva #princetonnnj #wth #lisbon #sfdc Arnab Sikder Ralph Lynn

Upcoming Webinar on April 17th co-hosted by Marbls and AstraZeneca! In collaboration with AstraZeneca, Marbls is excited to invite you to a webinar on the Informa Connect Life Sciences platform. We’ll dive into the latest updates around State Price Transparency Reporting legislation and how these laws continue to impact pharmaceutical manufacturers. Join us as we review the latest state requirements, the operational impacts they have on manufacturers around data collection and the importance of maintaining compliance with each state. Agenda Highlights: ·     Legislative updates and impacts on the reporting process ·     Evolving Prescription Drug Affordability Board (PDAB) landscape ·     Assumptions manufacturers must make around data to maintain compliance ·     Operational benefits of automation in your reporting practices The link to register for our webinar will be coming soon! If you’re interested in joining, please reach out to Ritu Pandey to learn more or let us know if you have any questions on price transparency reporting requirements. #lifesciences #drugpricing #drugprices #mobileapps #transparency #ourteam Arnab Sikder Ralph Lynn

Marbls is excited to sponsor the World Evidence, Pricing, and Access (EPA) Congress taking place in Amsterdam from March 5-6, 2025. Our colleagues Raquel Cunha Santos, Ruven Remo Eul, and Quinn McCartney will be at Booth 5 actively meeting with clients and partners on various topics. Raquel and Ruven will be presenting on March 6th at 13:00 on the topic of Successful Value Retention through Effective Loss of Exclusivity (LoE). For more information on the event or to schedule time with our team, please contact Raquel, Ruven, Quinn or anyone on our Marbls team. #lifesciences #marketaccess #pricing #contracting #tendering #ourteam Ralph Lynn Arnab Sikder

Loss of Exclusivity (LoE) represents a pivotal point in a pharmaceutical product's lifecycle when market exclusivity ends, opening the door to generic competition. Unfortunately, many companies fail to proactively plan and manage their LoE transitions, leaving them vulnerable to immense revenue erosion and market share loss. Our Principal and CCO, Ruven Remo Eul, shares Marbls' real world and client experience in his article about the “Successful Value Retention with Effective Loss of Exclusivity (LoE) Management”. In our paper we outline how to effectively plan and manage LoE to successfully retain value. To read the full article, please download at our website at https://lnkd.in/eXVG6H8w or get in touch with Ruven Remo Eul or themarblsteam@marblsgroup.com. #lifesciences #pricing #contracting #LoE #tendering #geneva #princetonnj #wth #lisbon Ralph Lynn Arnab Sikder

In recent years, the Life Sciences Industry has seen the advent of a new era in patient treatment — Digital Therapeutics, transforming and closing a gap within healthcare. In our latest whitepaper, our colleagues, Lindsey Kinard and Raquel Cunha Santos, explore the world of Digital Therapeutics. We review current and future Market Insights, discuss approval processes throughout the world, touch on success stories improving the lives of patients and highlight the challenges that the pharmaceutical industry may face when introducing a DTx and how to create successful business strategies. To access the article, please go to https://lnkd.in/e4wDy8Jz. For information on how Marbls is helping companies drive innovation within Digital Therpaeutics, please contact Lindsey, Raquel, or anyone on our Marbls team. #lifesciences #digitaltherapeutics #pricing #contracting #marketaccess #ourteam Ralph Lynn Arnab Sikder

Ahead of schedule, and just before the turnover in administration, CMS announced late last week the next set of Medicare Part D drugs selected for price negotiation. Manufacturers of these 15 drugs now have until February 28th to sign agreements to participate in the Negotiation Program.  Once negotiations are finalized, the MFPs (maximum fair price) for these drugs will be effective beginning January 2027. As the news was released, many were quick to call out the accurate predictions of Novo Nordisk’s Ozempic/Wegovy/Rybelsus landing on the list.  Aside from the additional Ozempic PR, here are some of Marbls key takeaways from the new list: -             70% of the drugs selected for the first round of price negotiations covered the conditions of diabetes, leukemia/lymphoma, and autoimmune diseases like psoriasis and psoriatic arthritis. CMS shows no signs of slowing down on curbing expenditures for these diseases, with one third of the latest released list targeting similar drugs. -             About half of the selections on the newest list are targeting drugs indicated to treat COPD/asthma, various types of cancer, and chronic bowel disorders. Given the trend mentioned above, will drugs for these new disease states also continue to be a target in future negotiation years? -             The latest list doesn’t just show trends in conditions treated, but with the manufacturers as well. The count of MFP drugs under a given manufacturer is up for several big pharma with companies like AbbVie, BMS, AstraZeneca, Boehringer Ingelheim, Amgen, Novo Nordisk, and Merck seeing an uptick in their drugs being selected for the program, year over year. As 2025 price negotiations kick off it will be interesting to see how their prior experience with the negotiation process will influence their strategy in 2025. -             There are also some new kids on the block with the latest list bringing additional manufacturers into the fold – some getting targeted with multiple drugs selected for negotiation at once. We’ll be breaking all of this down and more in our upcoming IRA White Paper series – and we’re kicking it off with MFP! In the meantime, feel free to reach out to anyone on the Marbls team or themarblsteam@marblsgroup.com for further insights on any of the IRA components. #lifesciences #pricing #contracting #MedicareUpdates Amber Daly Arnab Sikder Ralph Lynn

Piotr Klimiuk, Manager within the Marbls Warsaw Tech Hub (WTH) and expert in all things Salesforce, details how effective Managed Packages can be used to drive innovation and simplify compliance processes. Our team utilizes these methods in our solutions including our market leading State Price Transparency product, #spark. For more information or to discuss how Marbls can drive your Salesforce solutions, please contact Piotr or anyone on our Marbls team. #ourteam #lifesciences #pricing #contracting #salesforce #wth Ralph Lynn Arnab Sikder